Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19674713 | 0.83 | KDM4E (0.54) | SMN1; SMN2KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL14954856 | 0.82 | MAPT (0.50) | SMN1; SMN2KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL10272299 | 0.82 | MAPT (0.52) | SMN1; SMN2KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL19664913 | 0.79 | SMN1; SMN2 (0.54) | SMN1; SMN2KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL10272301 | 0.78 | MAPT (0.49) | SMN1; SMN2KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL3294834 | 0.78 | CYP2C19 (0.49) | KDM4EMAPTALDH1A1HPGDGAA | |
| SCHEMBL31647697 | 0.76 | KMT2A (0.60) | SMN1; SMN2KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL1036005 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EMAPTALDH1A1HPGD | |
| SCHEMBL29757605 | 0.76 | CYP2C19 (0.47) | KDM4EMAPTALDH1A1HPGDGAA | |
| SCHEMBL5624979 | 0.76 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230084927-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | METABOMED LTD. (IL) | 2023-03-16 | — | — | US | disclosed |
| EP-4058027-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | Metabomed Ltd (IL) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021095032-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | METABOMED LTD (IL) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021095032-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | METABOMED LTD (IL) | 2021-05-20 | — | — | WO | disclosed |
| US-20110046130-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046130-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046130-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2268638-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009121812-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009121812-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046130-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH4, HRH3, HRH1 | SMN1; SMN2 4504/4885KDM4E 467/4885MAPT 2721/4885 |
| US-20230084927-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | SLC2A4, SLC2A1, SLC2A2 | SMN1; SMN2 3756/4885KDM4E 2887/4885MAPT 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.